{
  "metadata": {
    "harmonization_date": "2025-07-03T20:30:52.186942",
    "version": "1.0",
    "description": "Harmonized pharmaceutical pipeline data from Novo Nordisk, Pfizer, and Novartis",
    "data_sources": [
      {
        "company": "novo_nordisk",
        "source_url": "https://www.novonordisk.com/science-and-technology/r-d-pipeline.html",
        "extraction_date": "2025-07-03"
      },
      {
        "company": "pfizer",
        "source_url": "https://www.pfizer.com/science/drug-product-pipeline",
        "extraction_date": "2025-07-03"
      },
      {
        "company": "novartis",
        "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
        "extraction_date": "2025-07-03"
      }
    ],
    "total_companies": 3,
    "total_candidates": 77
  },
  "companies": [
    {
      "company_name": "Novo Nordisk",
      "company_code": "NVO",
      "data_source": "https://www.novonordisk.com/science-and-technology/r-d-pipeline.html",
      "extraction_date": "2025-07-03",
      "pipeline_overview": {
        "description": "At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions. Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, cardiovascular disease, rare blood and endocrine disorders, and other serious chronic diseases.",
        "therapy_areas": [
          "Diabetes",
          "Obesity",
          "Cardiovascular Disease",
          "Emerging Therapy Areas",
          "Rare Blood Disorders",
          "Rare Endocrine Disorders"
        ],
        "development_phases": [
          "Phase 1",
          "Phase 2",
          "Phase 3",
          "Filed"
        ]
      },
      "total_candidates": 47,
      "phase_distribution": {
        "Phase 1": 19,
        "Phase 2": 13,
        "Phase 3": 10,
        "Registration/Filed": 5
      }
    },
    {
      "company_name": "Pfizer",
      "company_code": "PFE",
      "data_source": "https://www.pfizer.com/science/drug-product-pipeline",
      "extraction_date": "2025-07-03",
      "pipeline_overview": {
        "description": "We're in relentless pursuit of medicines and vaccines that will benefit patients around the world. Our ambitions are big and our product pipeline has never been stronger.",
        "areas_of_focus": [
          "Inflammation & Immunology",
          "Internal Medicine",
          "Oncology",
          "Vaccines"
        ],
        "development_phases": [
          "Phase 1",
          "Phase 2",
          "Phase 3",
          "Registration"
        ],
        "submission_types": [
          "New Molecular Entity",
          "Product Enhancement"
        ],
        "compound_types": [
          "Biologic",
          "Small Molecule",
          "Vaccine"
        ]
      },
      "total_candidates": 108,
      "phase_distribution": {
        "Phase 1": 47,
        "Phase 2": 28,
        "Phase 3": 30,
        "Registration/Filed": 3
      }
    },
    {
      "company_name": "Novartis",
      "company_code": "NVS",
      "data_source": "https://www.novartis.com/research-development/novartis-pipeline",
      "extraction_date": "2025-07-03",
      "pipeline_overview": {
        "description": "Benefiting from our continued focus on innovation, Novartis has one of the industry's most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide.",
        "therapeutic_areas": [
          "Oncology: Solid Tumors",
          "Oncology: Hematology",
          "Immunology",
          "Neuroscience",
          "In-market Brands and Global Health"
        ],
        "development_phases": [
          "Phase 1",
          "Phase 2",
          "Phase 3",
          "Registration"
        ]
      },
      "total_candidates": 20,
      "phase_distribution": {
        "Phase 1": 5,
        "Phase 2": 6,
        "Phase 3": 8,
        "Registration/Filed": 1
      }
    }
  ],
  "unified_pipeline": [
    {
      "candidate_id": "NVO_001",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Pumpsulin",
      "compound_code": "NN1471/Insulin 119",
      "brand_name": null,
      "indication": "Type 1 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel insulin analogue ideal for use in a closed loop pump device as delivery.",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Pumpsulin",
        "code": "NN1471/Insulin 119",
        "indication": "Type 1 diabetes",
        "therapy_area": "Diabetes",
        "description": "A novel insulin analogue ideal for use in a closed loop pump device as delivery."
      }
    },
    {
      "candidate_id": "NVO_002",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Glucose sensitive insulin",
      "compound_code": "NN1845/GSI/Insulin 845",
      "brand_name": null,
      "indication": "Type 1 and 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A glucose-sensitive insulin analogue intended for once-daily treatment.",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Glucose sensitive insulin",
        "code": "NN1845/GSI/Insulin 845",
        "indication": "Type 1 and 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A glucose-sensitive insulin analogue intended for once-daily treatment."
      }
    },
    {
      "candidate_id": "NVO_003",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "DNA immunotherapy",
      "compound_code": "NN9041",
      "brand_name": null,
      "indication": "Type 1 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function.",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "DNA immunotherapy",
        "code": "NN9041",
        "indication": "Type 1 diabetes",
        "therapy_area": "Diabetes",
        "description": "A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function."
      }
    },
    {
      "candidate_id": "NVO_004",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Amylin 355",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once-weekly subcutaneous amylin analogue for the treatment of obesity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Amylin 355",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous amylin analogue for the treatment of obesity"
      }
    },
    {
      "candidate_id": "NVO_005",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Amycretin",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Amycretin",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment"
      }
    },
    {
      "candidate_id": "NVO_006",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Subcutaneous Amycretin",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Subcutaneous Amycretin",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection"
      }
    },
    {
      "candidate_id": "NVO_007",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "INV-347",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "Next generation oral small molecule CB1 receptor blocker",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "INV-347",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "Next generation oral small molecule CB1 receptor blocker"
      }
    },
    {
      "candidate_id": "NVO_008",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "UBT251 (GGG tri-agonist)",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity, type 2 diabetes and other diseases",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A triple agonist of the receptors for GLP-1, GIP, and glucagon",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "UBT251 (GGG tri-agonist)",
        "indication": "Obesity, type 2 diabetes and other diseases",
        "therapy_area": "Obesity",
        "description": "A triple agonist of the receptors for GLP-1, GIP, and glucagon"
      }
    },
    {
      "candidate_id": "NVO_009",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Amylin 1213",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once-weekly subcutaneous amylin analogue for the treatment of obesity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Amylin 1213",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous amylin analogue for the treatment of obesity"
      }
    },
    {
      "candidate_id": "NVO_010",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Tri-agonist",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once-weekly subcutaneous tri-agonist for the treatment of obesity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Tri-agonist",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous tri-agonist for the treatment of obesity"
      }
    },
    {
      "candidate_id": "NVO_011",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Anti ANGPTL3",
      "compound_code": "",
      "brand_name": null,
      "indication": "Cardiovascular disease",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A monoclonal antibody in development for cardiovascular disease",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Anti ANGPTL3",
        "indication": "Cardiovascular disease",
        "therapy_area": "Cardiovascular Disease",
        "description": "A monoclonal antibody in development for cardiovascular disease"
      }
    },
    {
      "candidate_id": "NVO_012",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "CNP",
      "compound_code": "",
      "brand_name": null,
      "indication": "Heart failure",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A C-type natriuretic peptide (CNP) analogue in development for heart failure",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CNP",
        "indication": "Heart failure",
        "therapy_area": "Cardiovascular Disease",
        "description": "A C-type natriuretic peptide (CNP) analogue in development for heart failure"
      }
    },
    {
      "candidate_id": "NVO_013",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "NLRP3 inhibitor",
      "compound_code": "",
      "brand_name": null,
      "indication": "Cardiovascular disease",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "An oral treatment in a broad range of liver, kidney and cardiometabolic diseases",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "NLRP3 inhibitor",
        "indication": "Cardiovascular disease",
        "therapy_area": "Cardiovascular Disease",
        "description": "An oral treatment in a broad range of liver, kidney and cardiometabolic diseases"
      }
    },
    {
      "candidate_id": "NVO_014",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Cell Therapy in heart failure",
      "compound_code": "",
      "brand_name": null,
      "indication": "Heart failure",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Cell Therapy",
      "mechanism_of_action": "A cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Cell Therapy in heart failure",
        "indication": "Heart failure",
        "therapy_area": "Cardiovascular Disease",
        "description": "A cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC)"
      }
    },
    {
      "candidate_id": "NVO_015",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "MARC1",
      "compound_code": "",
      "brand_name": null,
      "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 1",
      "compound_type": "RNA Therapy",
      "mechanism_of_action": "An siRNA targeting MARC1 for subcutaneous treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "MARC1",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "An siRNA targeting MARC1 for subcutaneous treatment"
      }
    },
    {
      "candidate_id": "NVO_016",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "LXRα",
      "compound_code": "",
      "brand_name": null,
      "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 1",
      "compound_type": "RNA Therapy",
      "mechanism_of_action": "An siRNA targeting LXRα for subcutaneous treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "LXRα",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "An siRNA targeting LXRα for subcutaneous treatment"
      }
    },
    {
      "candidate_id": "NVO_017",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Cell therapy in Parkinson's disease",
      "compound_code": "",
      "brand_name": null,
      "indication": "Parkinson's Disease",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 1",
      "compound_type": "Cell Therapy",
      "mechanism_of_action": "A cell therapy using stem cell-derived nerve cells",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Cell therapy in Parkinson's disease",
        "indication": "Parkinson's Disease",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A cell therapy using stem cell-derived nerve cells"
      }
    },
    {
      "candidate_id": "NVO_018",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Inno8",
      "compound_code": "",
      "brand_name": null,
      "indication": "Haemophilia",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "An oral, once-daily antibody fragment for the treatment of haemophilia",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Inno8",
        "indication": "Haemophilia",
        "therapy_area": "Rare Blood Disorders",
        "description": "An oral, once-daily antibody fragment for the treatment of haemophilia"
      }
    },
    {
      "candidate_id": "NVO_019",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "TMPRSS6",
      "compound_code": "",
      "brand_name": null,
      "indication": "Hereditary Haemochromatosis",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "An RNAi in development for the rare blood disease Hereditary Haemochromatosis",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "TMPRSS6",
        "indication": "Hereditary Haemochromatosis",
        "therapy_area": "Rare Blood Disorders",
        "description": "An RNAi in development for the rare blood disease Hereditary Haemochromatosis"
      }
    },
    {
      "candidate_id": "NVO_020",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Subcutaneous Amycretin",
      "compound_code": "",
      "brand_name": null,
      "indication": "Diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Subcutaneous Amycretin",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection"
      }
    },
    {
      "candidate_id": "NVO_021",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Monlunabant in DKD",
      "compound_code": "INV-202",
      "brand_name": null,
      "indication": "Diabetic Kidney Disease (DKD)",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "An oral small molecule CB1 receptor blocker",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Monlunabant in DKD",
        "code": "INV-202",
        "indication": "Diabetic Kidney Disease (DKD)",
        "therapy_area": "Diabetes",
        "description": "An oral small molecule CB1 receptor blocker"
      }
    },
    {
      "candidate_id": "NVO_022",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Once weekly GLP-1/GIP",
      "compound_code": "",
      "brand_name": null,
      "indication": "Diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Once weekly GLP-1/GIP",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist"
      }
    },
    {
      "candidate_id": "NVO_023",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Amycretin",
      "compound_code": "",
      "brand_name": null,
      "indication": "Diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Amycretin",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment"
      }
    },
    {
      "candidate_id": "NVO_024",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "FUSE",
      "compound_code": "NN9506",
      "brand_name": null,
      "indication": "Type 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "FUSE",
        "code": "NN9506",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment"
      }
    },
    {
      "candidate_id": "NVO_025",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "FUSE",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "FUSE",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment"
      }
    },
    {
      "candidate_id": "NVO_026",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Once weekly GLP-1/GIP",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Once weekly GLP-1/GIP",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist"
      }
    },
    {
      "candidate_id": "NVO_027",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Monlunabant",
      "compound_code": "INV-202",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "An oral small molecule CB1 receptor blocker",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Monlunabant",
        "code": "INV-202",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "An oral small molecule CB1 receptor blocker"
      }
    },
    {
      "candidate_id": "NVO_028",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "CDR132L",
      "compound_code": "",
      "brand_name": null,
      "indication": "Heart failure with reduced ejection fraction (HFrEF)",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "An antisense oligonucleotide (ASO) targeting the microRNA molecule miR-132",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CDR132L",
        "indication": "Heart failure with reduced ejection fraction (HFrEF)",
        "therapy_area": "Cardiovascular Disease",
        "description": "An antisense oligonucleotide (ASO) targeting the microRNA molecule miR-132"
      }
    },
    {
      "candidate_id": "NVO_029",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "NDec",
      "compound_code": "Eclipse/EPI01/NN7533",
      "brand_name": null,
      "indication": "Sickle cell disease",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "An oral combination of decitabine and tetrahydrouridine",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "NDec",
        "code": "Eclipse/EPI01/NN7533",
        "indication": "Sickle cell disease",
        "therapy_area": "Rare Blood Disorders",
        "description": "An oral combination of decitabine and tetrahydrouridine"
      }
    },
    {
      "candidate_id": "NVO_030",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Coramitug",
      "compound_code": "PRX004/NN6019",
      "brand_name": null,
      "indication": "ATTR Cardiomyopathy",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "An anti-amyloid immunotherapy treatment for ATTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Coramitug",
        "code": "PRX004/NN6019",
        "indication": "ATTR Cardiomyopathy",
        "therapy_area": "Cardiovascular Disease",
        "description": "An anti-amyloid immunotherapy treatment for ATTR"
      }
    },
    {
      "candidate_id": "NVO_031",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Zalfermin",
      "compound_code": "NN9500",
      "brand_name": null,
      "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting FGF21 analogue for once-weekly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Zalfermin",
        "code": "NN9500",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A long-acting FGF21 analogue for once-weekly treatment"
      }
    },
    {
      "candidate_id": "NVO_032",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Etavopivat",
      "compound_code": "",
      "brand_name": null,
      "indication": "Thalassemia",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "A selective pyruvate kinase-R (PKR) activator intended for once daily oral treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Etavopivat",
        "indication": "Thalassemia",
        "therapy_area": "Rare Blood Disorders",
        "description": "A selective pyruvate kinase-R (PKR) activator intended for once daily oral treatment"
      }
    },
    {
      "candidate_id": "NVO_033",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Semaglutide 25 mg and 50 mg",
      "compound_code": "NN9924",
      "brand_name": null,
      "indication": "Type 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 3",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "Oral GLP-1 25 and 50 mg, intended for once-daily treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Semaglutide 25 mg and 50 mg",
        "code": "NN9924",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "Oral GLP-1 25 and 50 mg, intended for once-daily treatment"
      }
    },
    {
      "candidate_id": "NVO_034",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "CagriSema in T2D",
      "compound_code": "NN9388",
      "brand_name": null,
      "indication": "Type 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "A combination of amylin analogue and GLP-1 analogue semaglutide intended for once-weekly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CagriSema in T2D",
        "code": "NN9388",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A combination of amylin analogue and GLP-1 analogue semaglutide intended for once-weekly treatment"
      }
    },
    {
      "candidate_id": "NVO_035",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "CagriSema",
      "compound_code": "NN9898",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "A combination of amylin analogue cagrilintide and GLP-1 analogue semaglutide intended for once-weekly subcutaneous treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CagriSema",
        "code": "NN9898",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A combination of amylin analogue cagrilintide and GLP-1 analogue semaglutide intended for once-weekly subcutaneous treatment"
      }
    },
    {
      "candidate_id": "NVO_036",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Semaglutide 7.2 mg",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Semaglutide 7.2 mg",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity"
      }
    },
    {
      "candidate_id": "NVO_037",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Ziltivekimab ASCVD",
      "compound_code": "NN6018",
      "brand_name": null,
      "indication": "Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD) and inflammation",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Ziltivekimab ASCVD",
        "code": "NN6018",
        "indication": "Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD) and inflammation",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      }
    },
    {
      "candidate_id": "NVO_038",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Ziltivekimabin HFpEF",
      "compound_code": "",
      "brand_name": null,
      "indication": "Heart failure with preserved ejection fraction (HFpEF)",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Ziltivekimabin HFpEF",
        "indication": "Heart failure with preserved ejection fraction (HFpEF)",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      }
    },
    {
      "candidate_id": "NVO_039",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Ziltivekimab AMI",
      "compound_code": "",
      "brand_name": null,
      "indication": "Acute Myocardial infarction (AMI)",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Ziltivekimab AMI",
        "indication": "Acute Myocardial infarction (AMI)",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      }
    },
    {
      "candidate_id": "NVO_040",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Semaglutide Alzheimer's",
      "compound_code": "",
      "brand_name": null,
      "indication": "Alzheimer's disease",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 3",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "Oral semaglutide 14 mg once-daily for the treatment of early Alzheimer's disease",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Semaglutide Alzheimer's",
        "indication": "Alzheimer's disease",
        "therapy_area": "Emerging Therapy Areas",
        "description": "Oral semaglutide 14 mg once-daily for the treatment of early Alzheimer's disease"
      }
    },
    {
      "candidate_id": "NVO_041",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Mim8",
      "compound_code": "NN7769",
      "brand_name": null,
      "indication": "Haemophilia A with or without inhibitors",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Mim8",
        "code": "NN7769",
        "indication": "Haemophilia A with or without inhibitors",
        "therapy_area": "Rare Blood Disorders",
        "description": "A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis"
      }
    },
    {
      "candidate_id": "NVO_042",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Etavopivat (Sickle Cell Disease)",
      "compound_code": "",
      "brand_name": null,
      "indication": "Sickle Cell Disease",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 3",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "Oral, small molecule activator of erythrocyte pyruvate kinase (PKR)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Etavopivat (Sickle Cell Disease)",
        "indication": "Sickle Cell Disease",
        "therapy_area": "Rare Blood Disorders",
        "description": "Oral, small molecule activator of erythrocyte pyruvate kinase (PKR)"
      }
    },
    {
      "candidate_id": "NVO_043",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Icosema",
      "compound_code": "NN1535/LAIsema",
      "brand_name": null,
      "indication": "Type 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Registration/Filed",
      "compound_type": "Biologic",
      "mechanism_of_action": "A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Icosema",
        "code": "NN1535/LAIsema",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment"
      }
    },
    {
      "candidate_id": "NVO_044",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Insulin icodec",
      "compound_code": "NN1436/LAI287",
      "brand_name": null,
      "indication": "Type 1 and 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Registration/Filed",
      "compound_type": "Biologic",
      "mechanism_of_action": "A long-acting basal insulin analogue intended for once weekly dosing",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Insulin icodec",
        "code": "NN1436/LAI287",
        "indication": "Type 1 and 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting basal insulin analogue intended for once weekly dosing"
      }
    },
    {
      "candidate_id": "NVO_045",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Sema Obesity",
      "compound_code": "NN9932",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Registration/Filed",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long acting GLP-1 analogue intended for once-daily treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Sema Obesity",
        "code": "NN9932",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long acting GLP-1 analogue intended for once-daily treatment"
      }
    },
    {
      "candidate_id": "NVO_046",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Semaglutide MASH",
      "compound_code": "",
      "brand_name": null,
      "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Registration/Filed",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting GLP-1 analogue for once-weekly treatment of MASH",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Semaglutide MASH",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A long-acting GLP-1 analogue for once-weekly treatment of MASH"
      }
    },
    {
      "candidate_id": "NVO_047",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Concizumab",
      "compound_code": "",
      "brand_name": null,
      "indication": "Haemophilia A and B with inhibitors",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Registration/Filed",
      "compound_type": "Unknown",
      "mechanism_of_action": "Treatment for haemophilia A and B with inhibitors",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Concizumab",
        "indication": "Haemophilia A and B with inhibitors",
        "therapy_area": "Rare Blood Disorders",
        "description": "Treatment for haemophilia A and B with inhibitors"
      }
    },
    {
      "candidate_id": "PFE_001",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "ABRYSVO",
      "compound_code": null,
      "brand_name": null,
      "indication": "Respiratory Syncytial Virus Infection (pediatric)",
      "therapeutic_area": "Vaccines",
      "development_phase": "Phase 1",
      "compound_type": "Vaccine",
      "mechanism_of_action": null,
      "submission_type": "Product Enhancement",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "ABRYSVO",
        "indication": "Respiratory Syncytial Virus Infection (pediatric)",
        "area_of_focus": "Vaccines",
        "submission_type": "Product Enhancement",
        "compound_type": "Vaccine",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_002",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "CTB+AVP (PF-07612577)",
      "compound_code": "PF-07612577",
      "brand_name": null,
      "indication": "Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis (FAST TRACK - U.S.)",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [
        "Fast Track"
      ],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CTB+AVP (PF-07612577)",
        "indication": "Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis (FAST TRACK - U.S.)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_003",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "Dekavil",
      "compound_code": null,
      "brand_name": null,
      "indication": "Rheumatoid Arthritis (Biologic)",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Dekavil",
        "indication": "Rheumatoid Arthritis (Biologic)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_004",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "felmetatug vedotin (PF-08046048) (B7H4V)",
      "compound_code": "PF-08046048",
      "brand_name": null,
      "indication": "Advanced Solid Tumors (Biologic)",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "felmetatug vedotin (PF-08046048) (B7H4V)",
        "indication": "Advanced Solid Tumors (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_005",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PADCEV (enfortumab vedotin)",
      "compound_code": null,
      "brand_name": null,
      "indication": "BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "Product Enhancement",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PADCEV (enfortumab vedotin)",
        "indication": "BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "Product Enhancement",
        "compound_type": "Biologic",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_006",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-06414300",
      "compound_code": "PF-06414300",
      "brand_name": null,
      "indication": "Ulcerative Colitis",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-06414300",
        "indication": "Ulcerative Colitis",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_007",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-06835375",
      "compound_code": "PF-06835375",
      "brand_name": null,
      "indication": "Lupus (Biologic)",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "Product Enhancement",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-06835375",
        "indication": "Lupus (Biologic)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "Product Enhancement",
        "compound_type": "Biologic",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_008",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-06940434",
      "compound_code": "PF-06940434",
      "brand_name": null,
      "indication": "Advanced Solid Tumors (Biologic)",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-06940434",
        "indication": "Advanced Solid Tumors (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_009",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-06954522",
      "compound_code": "PF-06954522",
      "brand_name": null,
      "indication": "Chronic Weight Management",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-06954522",
        "indication": "Chronic Weight Management",
        "area_of_focus": "Internal Medicine",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      }
    },
    {
      "candidate_id": "PFE_010",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-07054894",
      "compound_code": "PF-07054894",
      "brand_name": null,
      "indication": "Inflammatory Bowel Disease",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-07054894",
        "indication": "Inflammatory Bowel Disease",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      }
    },
    {
      "candidate_id": "NVS_001",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Gastroenteropancreatic neuroendocrine tumors",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 3",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "Gastroenteropancreatic neuroendocrine tumors",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 3",
        "mechanism": "Radioligand therapy target SSTR"
      }
    },
    {
      "candidate_id": "NVS_002",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "GEPNET, pediatrics",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "GEPNET, pediatrics",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "mechanism": "Radioligand therapy target SSTR"
      }
    },
    {
      "candidate_id": "NVS_003",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Glioblastoma",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "Glioblastoma",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "mechanism": "Radioligand therapy target SSTR"
      }
    },
    {
      "candidate_id": "NVS_004",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "1L ES-SCLC",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "1L ES-SCLC",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "mechanism": "Radioligand therapy target SSTR"
      }
    },
    {
      "candidate_id": "NVS_005",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Gastroenteropancreatic neuroendocrine tumors (GEP-NET), 1st line in G2/3 tumors",
      "therapeutic_area": "Oncology",
      "development_phase": "Registration/Filed",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2024",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "Gastroenteropancreatic neuroendocrine tumors (GEP-NET), 1st line in G2/3 tumors",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Registration",
        "filing_date": "2024",
        "mechanism": "Radioligand therapy target SSTR"
      }
    },
    {
      "candidate_id": "NVS_006",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA603",
      "compound_code": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Breast cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target GRPR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "≥ 2028",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA603",
        "brand_name": "177Lu-NeoB",
        "indication": "Breast cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "filing_date": "≥ 2028",
        "mechanism": "Radioligand therapy target GRPR"
      }
    },
    {
      "candidate_id": "NVS_007",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA603",
      "compound_code": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Glioblastoma multiforme",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target GRPR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "≥ 2028",
      "lead_indication": true,
      "status": "Current",
      "source_data": {
        "compound": "AAA603",
        "brand_name": "177Lu-NeoB",
        "indication": "Glioblastoma multiforme",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "filing_date": "≥ 2028",
        "mechanism": "Radioligand therapy target GRPR",
        "lead_indication": true
      }
    },
    {
      "candidate_id": "NVS_008",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA603",
      "compound_code": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Multiple solid tumors",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target GRPR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "≥ 2028",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA603",
        "brand_name": "177Lu-NeoB",
        "indication": "Multiple solid tumors",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "filing_date": "≥ 2028",
        "mechanism": "Radioligand therapy target GRPR"
      }
    },
    {
      "candidate_id": "NVS_009",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA614",
      "compound_code": "AAA614",
      "brand_name": "AAA614",
      "indication": "Solid tumors",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target FAP",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": true,
      "status": "Current",
      "source_data": {
        "compound": "AAA614",
        "brand_name": "AAA614",
        "indication": "Solid tumors",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "mechanism": "Radioligand therapy target FAP",
        "lead_indication": true
      }
    },
    {
      "candidate_id": "NVS_010",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA617",
      "compound_code": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Metastatic hormone sensitive prostate cancer (mHSPC)",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 3",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2025",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA617",
        "brand_name": "Pluvicto®",
        "indication": "Metastatic hormone sensitive prostate cancer (mHSPC)",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 3",
        "filing_date": "2025",
        "mechanism": "Radioligand therapy target PSMA"
      }
    },
    {
      "candidate_id": "NVS_011",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA617",
      "compound_code": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Oligometastatic prostate cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 3",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2027",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA617",
        "brand_name": "Pluvicto®",
        "indication": "Oligometastatic prostate cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 3",
        "filing_date": "2027",
        "mechanism": "Radioligand therapy target PSMA"
      }
    },
    {
      "candidate_id": "NVS_012",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA617",
      "compound_code": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Metastatic neuroendocrine prostate cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2025",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA617",
        "brand_name": "Pluvicto®",
        "indication": "Metastatic neuroendocrine prostate cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "filing_date": "2025",
        "mechanism": "Radioligand therapy target PSMA"
      }
    },
    {
      "candidate_id": "NVS_013",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA802",
      "compound_code": "AAA802",
      "brand_name": "225Ac-PSMA-R2",
      "indication": "Prostate cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": true,
      "status": "Current",
      "source_data": {
        "compound": "AAA802",
        "brand_name": "225Ac-PSMA-R2",
        "indication": "Prostate cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "mechanism": "Radioligand therapy target PSMA",
        "lead_indication": true
      }
    },
    {
      "candidate_id": "NVS_014",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA817",
      "compound_code": "AAA817",
      "brand_name": "225Ac-PSMA-617",
      "indication": "Metastatic castration-resistant prostate cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": true,
      "status": "Current",
      "source_data": {
        "compound": "AAA817",
        "brand_name": "225Ac-PSMA-617",
        "indication": "Metastatic castration-resistant prostate cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "mechanism": "Radioligand therapy target PSMA",
        "lead_indication": true
      }
    },
    {
      "candidate_id": "NVS_015",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "ABL001",
      "compound_code": "ABL001",
      "brand_name": "Scemblix®",
      "indication": "Chronic myeloid leukemia, pediatrics",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "BCR-ABL inhibitor",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "ABL001",
        "brand_name": "Scemblix®",
        "indication": "Chronic myeloid leukemia, pediatrics",
        "therapeutic_area": "Oncology: Hematology",
        "phase": "Phase 2",
        "mechanism": "BCR-ABL inhibitor"
      }
    },
    {
      "candidate_id": "NVS_016",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AIN457",
      "compound_code": "AIN457",
      "brand_name": "Cosentyx®",
      "indication": "Giant cell arteritis (GCA)",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2025",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AIN457",
        "brand_name": "Cosentyx®",
        "indication": "Giant cell arteritis (GCA)",
        "therapeutic_area": "Immunology",
        "phase": "Phase 3",
        "filing_date": "2025",
        "mechanism": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)",
        "supplementary_indication": true
      }
    },
    {
      "candidate_id": "NVS_017",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AIN457",
      "compound_code": "AIN457",
      "brand_name": "Cosentyx®",
      "indication": "Polymyalgia rheumatica",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2026",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AIN457",
        "brand_name": "Cosentyx®",
        "indication": "Polymyalgia rheumatica",
        "therapeutic_area": "Immunology",
        "phase": "Phase 3",
        "filing_date": "2026",
        "mechanism": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)"
      }
    },
    {
      "candidate_id": "NVS_018",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AMG334",
      "compound_code": "AMG334",
      "brand_name": "Aimovig®",
      "indication": "Migraine, pediatrics",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "CGRPR antagonist",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2027",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AMG334",
        "brand_name": "Aimovig®",
        "indication": "Migraine, pediatrics",
        "therapeutic_area": "In-market Brands and Global Health",
        "phase": "Phase 3",
        "filing_date": "2027",
        "mechanism": "CGRPR antagonist"
      }
    },
    {
      "candidate_id": "NVS_019",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "BAF312",
      "compound_code": "BAF312",
      "brand_name": "Mayzent®",
      "indication": "Multiple sclerosis, pediatrics",
      "therapeutic_area": "Neuroscience",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "S1P1 Modulator (Sphingosine-1-phosphate receptor modulator)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2027",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "BAF312",
        "brand_name": "Mayzent®",
        "indication": "Multiple sclerosis, pediatrics",
        "therapeutic_area": "Neuroscience",
        "phase": "Phase 3",
        "filing_date": "2027",
        "mechanism": "S1P1 Modulator (Sphingosine-1-phosphate receptor modulator)",
        "supplementary_indication": true
      }
    },
    {
      "candidate_id": "NVS_020",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "BYL719",
      "compound_code": "BYL719",
      "brand_name": "Vijoyce®",
      "indication": "Lymphatic malformations",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "PI3K-alpha inhibitor",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2027",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "BYL719",
        "brand_name": "Vijoyce®",
        "indication": "Lymphatic malformations",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 3",
        "filing_date": "2027",
        "mechanism": "PI3K-alpha inhibitor"
      }
    }
  ],
  "therapeutic_areas": [
    "Cardiovascular/Metabolic",
    "Diabetes",
    "Immunology",
    "Neuroscience",
    "Obesity",
    "Oncology",
    "Other/Emerging",
    "Rare Diseases",
    "Vaccines"
  ],
  "development_phases": [
    "Phase 1",
    "Phase 2",
    "Phase 3",
    "Registration/Filed"
  ],
  "compound_types": [
    "Biologic",
    "Cell Therapy",
    "RNA Therapy",
    "Radioligand",
    "Small Molecule",
    "Unknown",
    "Vaccine"
  ],
  "mechanisms_of_action": [
    "A C-type natriuretic peptide (CNP) analogue in development for heart failure",
    "A cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC)",
    "A cell therapy using stem cell-derived nerve cells",
    "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment",
    "A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment",
    "A combination of amylin analogue and GLP-1 analogue semaglutide intended for once-weekly treatment",
    "A combination of amylin analogue cagrilintide and GLP-1 analogue semaglutide intended for once-weekly subcutaneous treatment",
    "A glucose-sensitive insulin analogue intended for once-daily treatment.",
    "A long acting GLP-1 analogue intended for once-daily treatment",
    "A long-acting FGF21 analogue for once-weekly treatment",
    "A long-acting GLP-1 analogue for once-weekly treatment of MASH",
    "A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity",
    "A long-acting basal insulin analogue intended for once weekly dosing",
    "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment",
    "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection",
    "A monoclonal antibody in development for cardiovascular disease",
    "A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis",
    "A novel insulin analogue ideal for use in a closed loop pump device as delivery.",
    "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity",
    "A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function.",
    "A once weekly subcutaneous dual GLP-1/GIP receptor agonist",
    "A once-weekly subcutaneous amylin analogue for the treatment of obesity",
    "A once-weekly subcutaneous tri-agonist for the treatment of obesity",
    "A selective pyruvate kinase-R (PKR) activator intended for once daily oral treatment",
    "A triple agonist of the receptors for GLP-1, GIP, and glucagon",
    "An RNAi in development for the rare blood disease Hereditary Haemochromatosis",
    "An anti-amyloid immunotherapy treatment for ATTR",
    "An antisense oligonucleotide (ASO) targeting the microRNA molecule miR-132",
    "An oral combination of decitabine and tetrahydrouridine",
    "An oral small molecule CB1 receptor blocker",
    "An oral treatment in a broad range of liver, kidney and cardiometabolic diseases",
    "An oral, once-daily antibody fragment for the treatment of haemophilia",
    "An siRNA targeting LXRα for subcutaneous treatment",
    "An siRNA targeting MARC1 for subcutaneous treatment",
    "BCR-ABL inhibitor",
    "CGRPR antagonist",
    "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)",
    "Next generation oral small molecule CB1 receptor blocker",
    "Oral GLP-1 25 and 50 mg, intended for once-daily treatment",
    "Oral semaglutide 14 mg once-daily for the treatment of early Alzheimer's disease",
    "Oral, small molecule activator of erythrocyte pyruvate kinase (PKR)",
    "PI3K-alpha inhibitor",
    "Radioligand therapy target FAP",
    "Radioligand therapy target GRPR",
    "Radioligand therapy target PSMA",
    "Radioligand therapy target SSTR",
    "S1P1 Modulator (Sphingosine-1-phosphate receptor modulator)",
    "Treatment for haemophilia A and B with inhibitors"
  ],
  "summary_statistics": {
    "total_candidates": 77,
    "by_company": {
      "Novo Nordisk": 47,
      "Pfizer": 10,
      "Novartis": 20
    },
    "by_phase": {
      "Phase 1": 34,
      "Phase 2": 19,
      "Phase 3": 18,
      "Registration/Filed": 6
    },
    "by_therapeutic_area": {
      "Diabetes": 12,
      "Obesity": 13,
      "Cardiovascular/Metabolic": 10,
      "Other/Emerging": 7,
      "Rare Diseases": 7,
      "Vaccines": 1,
      "Immunology": 7,
      "Oncology": 19,
      "Neuroscience": 1
    },
    "by_compound_type": {
      "Biologic": 19,
      "Unknown": 24,
      "Small Molecule": 15,
      "Cell Therapy": 2,
      "RNA Therapy": 2,
      "Vaccine": 1,
      "Radioligand": 14
    }
  }
}